Research Analysts Offer Predictions for NTLA FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Intellia Therapeutics to a loss of $3.06 per share from $3.00, while maintaining a Buy rating and a $25 price target. The broader consensus expects a $3.18 per-share loss.
• Intellia’s latest quarterly results matched expectations at a $0.80-per-share loss, but revenue of $7.66 million fell short of the $12.98 million forecast and declined 46.4% year over year.
• Analyst sentiment remains mixed: the stock has an average Hold rating and a $20.85 price target, while NTLA recently traded at $12.02 within a 52-week range of $7.95 to $28.25.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at HC Wainwright reduced their FY2026 earnings estimates for Intellia Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($3.06) per share for the year, down from their previous estimate of ($3.00). HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.18) per share. HC Wainwright also issued estimates for Intellia Therapeutics' Q3 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.12) EPS.

Several other brokerages have also recently commented on NTLA. The Goldman Sachs Group boosted their target price on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a "sell" rating in a research report on Tuesday, April 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Wedbush increased their target price on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the stock a "neutral" rating in a report on Friday, July 10th. Evercore upgraded shares of Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 target price on the stock in a research report on Friday. Finally, Wolfe Research downgraded Intellia Therapeutics from a "peer perform" rating to an "underperform" rating and set a $9.00 price objective on the stock. in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $20.85.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $12.02 on Tuesday. The stock has a market capitalization of $1.68 billion, a P/E ratio of -3.58 and a beta of 1.81. The stock's fifty day moving average is $13.61 and its 200 day moving average is $13.48. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The business had revenue of $7.66 million during the quarter, compared to analysts' expectations of $12.98 million. During the same period in the previous year, the company posted ($0.98) earnings per share. The firm's revenue for the quarter was down 46.4% compared to the same quarter last year.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently made changes to their positions in NTLA. Comerica Bank increased its position in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company's stock valued at $26,000 after buying an additional 901 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics during the third quarter valued at approximately $30,000. Advisory Services Network LLC acquired a new position in shares of Intellia Therapeutics during the third quarter worth approximately $33,000. Finally, Fifth Third Bancorp bought a new position in shares of Intellia Therapeutics in the 1st quarter worth $38,000. Institutional investors and hedge funds own 88.77% of the company's stock.

Insider Activity

In related news, EVP Edward J. Dulac III sold 4,677 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company's stock, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares of the company's stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source